Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention
Status:
Completed
Trial end date:
2021-05-12
Target enrollment:
Participant gender:
Summary
This randomized controlled trial will prospectively evaluate the clinical benefit for
subcutaneous methylnaltrexone (MNTX) in counteracting the obstipatory (causing constipation)
effects of spinal surgery without increasing narcotic usage or otherwise disrupting the
recovery course of patients. Using a double-blind randomized design, either subcutaneous MNTX
(0.15 mg/kg rounded to 8 mg or 12 mg) or placebo will be administered starting before surgery
and then daily for three days. Information will be collected from medical records in IHIS up
to 30 days prior to surgery and then for up to 30 days after surgery.